The introduction of Retatrutide ZPHC, at a dosage of 120mg, is generating considerable excitement within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication seems to deliver notable improvements in fat loss compared to current therapies. Preliminary research data have